Larvol Cliniclarvol.hashnode.devยทSep 27, 2024Gilteritinib Plus Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: Phase 3 Study Design and Preliminary ResultsBackground: Gilteritinib is an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor that has demonstrated efficacy with favorable tolerability in patients with FLT3-mutated (FLT3mut+) relapsed/refractory acute myeloid leukemia (AML), including internal t...CancerAdd a thoughtful commentNo comments yetBe the first to start the conversation.
